RM-046, a first-in-class, mutant-selective, and oral KRAS^Q61H(ON) inhibitor that drives tumor regression in preclinical models and validates KRAS^Q61H as a therapeutic target

Yu C. Yang, Severin Thompson, David Montgomery, Antonio J. Quinones, Xing Wei, Benjamin Madej, Aidan Tomlinson, Nataliya T. Shifrin, Alexander McNamara, Ethan Ahler,Laura L. McDowell, Michael Flagella, John Setser, Stephanie Chang,Zhican Wang,Zhengping Wang, Jun Huang, Steve Ballmer, Shaong Li, Andreas Buckl, Elena Koltun,Adrian Gill, Jingjing Jiang,Mallika Singh,Jacqueline A. Smith

CANCER RESEARCH（2023）

引用 0|浏览3

暂无评分

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要

RM-046, a first-in-class, mutant-selective, and oral KRASQ61H(ON) inhibitor that drives tumor regression in preclinical models and validates KRASQ61H as a therapeutic target

RM-046, a first-in-class, mutant-selective, and oral KRAS^Q61H(ON) inhibitor that drives tumor regression in preclinical models and validates KRAS^Q61H as a therapeutic target